References
- Boonsrirat U, Hongsakul K. Pharmacomechanical thrombolysis for the treatment of thrombosed native arteriovenous fistula: a single-center experience. Pol J Radiol. 2014; 79: 363–7. DOI: 10.12659/PJR.890801
- Haruguchi H, Teraoka S. Intimal hyperplasia and hemodynamic factors in arterial bypass and arteriovenous grafts: A review. J Artif Organs. 2003; 6: 227–35. DOI: 10.1007/s10047-003-0232-x
- Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol. 2000; 190: 300–9. DOI: 10.1002/(SICI)1096-9896(200002)190:3<;300::AID-PATH596>3.0.CO;2-I
- Lok CE, Huber TS, Lee T, et al. National Kidney Foundation. KDOQI Clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis. 2020; 75: S1–S164. DOI: 10.1053/j.ajkd.2019.12.001
- Karnabatidis D, Kitrou PM, Ponce P, et al. A multicenter global registry of paclitaxel drug-coated balloon in dysfunctional arteriovenous fistulae and grafts: 6-month results. J Vasc Interv Radiol. 2021; 32: 360–8.e2. DOI: 10.1016/j.jvir.2020.11.018
- Phang CC, Tan RY, Pang SC, et al. Paclitaxel-coated balloon in the treatment of recurrent dysfunctional arteriovenous access, real-world experience and longitudinal follow up. Nephrology (Carlton). 2019; 24: 1290–5. DOI: 10.1111/nep.13591
- Lee T, Mokrzycki M, Moist L, Maya I, Vazquez M, Lok CE. North American Vascular Access Consortium. Standardized definitions for hemodialysis vascular access. Semin Dial. 2011; 24: 515–24. DOI: 10.1111/j.1525-139X.2011.00969.x
- Gray RJ, Sacks D, Martin LG, Trerotola SO. Reporting standards for percutaneous interventions in dialysis access. Technology assessment committee. J Vasc Interv Radiol. 1999; 10: 1405–15. DOI: 10.1097/01.RVI.0000094618.61428.58
- Kelly PJ, Lim LL. Survival analysis for recurrent event data: An application to childhood infectious diseases. Stat Med. 2000; 19: 13–33. DOI: 10.1002/(SICI)1097-0258(20000115)19:1<;13::AID-SIM279>3.0.CO;2-5
- Crowther MJ. Multilevel mixed-effects parametric survival analysis: Estimation, simulation, and application. Stata J. 2019; 19: 931–49. DOI: 10.1177/1536867X19893639
- Yin D, Li J, Yang YJ, et al. Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions. J Geriatr Cardiol. 2017; 14: 35–41. DOI: 10.11909/j.issn.1671-5411.2017.01.009
- Ding Y, Zhou M, Wang Y, Cai L, Shi Z. Comparison of drug-eluting stent with bare-metal stent implantation in femoropopliteal artery disease: A systematic review and meta-analysis. Ann Vasc Surg. 2018; 50: 96–105. DOI: 10.1016/j.avsg.2017.12.003
- Yan Wee IJ, Yap HY, Hsien Ts’ung LT, et al. A systematic review and meta-analysis of drug-coated balloon versus conventional balloon angioplasty for dialysis access stenosis. J Vasc Surg. 2019; 70: 970–9. DOI: 10.1016/j.avsg.2017.12.003
- Irani FG, Teo TKB, Tay KH, et al. Hemodialysis arteriovenous fistula and graft stenoses: randomized trial comparing drug-eluting balloon angioplasty with conventional angioplasty. Radiology. 2018; 289: 238–47. DOI: 10.1148/radiol.2018170806
- Katsanos K, Karnabatidis D, Kitrou P, Spiliopoulos S, Christeas N, Siablis D. Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6-month interim results from a prospective randomized controlled trial. J Endovasc Ther. 2012; 19: 263–72. DOI: 10.1583/11-3690.1
- Lookstein RA, Haruguchi H, Ouriel K, et al. Drug-coated balloons for dysfunctional dialysis arteriovenous fistulas. N Engl J Med. 2020; 383: 733–42. DOI: 10.1056/NEJMoa1914617
- Cao Z, Li J, Zhang T, et al. Comparative effectiveness of drug-coated balloon vs balloon angioplasty for the treatment of arteriovenous fistula stenosis: a meta-analysis. J Endovasc Ther. 2020; 27: 266–75. DOI: 10.1177/1526602820902757